WINTON GROUP Ltd Buys New Position in AtriCure, Inc. $ATRC

Key Points

• WINTON GROUP Ltd acquired 35,800 AtriCure shares worth approximately $1.0 million in the second quarter, while institutional investors collectively own 99.11% of the company.
• Analysts maintain a generally positive outlook, with AtriCure receiving a consensus “Moderate Buy” rating and an average price target of $52.00. Recent targets range from $50 to $55, although Zacks downgraded the stock to “Hold.”
• AtriCure reported quarterly revenue of $153.6 million and earnings of $0.18 per share, exceeding estimates, and issued fiscal 2026 EPS guidance of $0.24–$0.32. The stock opened at $54.54, near its 52-week high of $55.72.

WINTON GROUP Ltd acquired a new stake in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 35,800 shares of the medical device company's stock, valued at approximately $1,002,000. WINTON GROUP Ltd owned 0.07% of AtriCure as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently bought and sold shares of the company. Bank of America Corp DE boosted its holdings in shares of AtriCure by 13.7% in the 1st quarter. Bank of America Corp DE now owns 768,561 shares of the medical device company's stock valued at $21,927,000 after purchasing an additional 92,830 shares during the last quarter. Man Group plc acquired a new stake in shares of AtriCure during the 2nd quarter worth $684,000. Assenagon Asset Management S.A. acquired a new stake in shares of AtriCure during the 2nd quarter worth $1,744,000. Rice Hall James & Associates LLC purchased a new position in shares of AtriCure in the 2nd quarter worth $3,755,000. Finally, Deutsche Bank AG purchased a new position in shares of AtriCure in the 2nd quarter worth $1,670,000. Institutional investors and hedge funds own 99.11% of the company's stock.

Insider Activity

In other AtriCure news, Director Sven Wehrwein sold 25,000 shares of the firm's stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $37.84, for a total transaction of $946,000.00. Following the completion of the transaction, the director directly owned 40,518 shares of the company's stock, valued at $1,533,201.12. This trade represents a 38.16% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Justin Noznesky sold 6,182 shares of the business's stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $38.80, for a total transaction of $239,861.60. Following the completion of the sale, the insider directly owned 100,219 shares of the company's stock, valued at $3,888,497.20. The trade was a 5.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 65,036 shares of company stock worth $2,758,687 over the last ninety days. Insiders own 4.00% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Raymond James Financial set a $52.00 target price on AtriCure in a report on Tuesday, July 21st. BTIG Research raised their price target on shares of AtriCure from $45.00 to $55.00 and gave the company a "buy" rating in a report on Monday, August 24th. Citigroup reaffirmed a "market outperform" rating on shares of AtriCure in a research report on Tuesday, July 21st. UBS Group decreased their price objective on shares of AtriCure from $55.00 to $50.00 and set a "buy" rating for the company in a research note on Tuesday, July 28th. Finally, Zacks Research lowered shares of AtriCure from a "strong-buy" rating to a "hold" rating in a research report on Monday, August 24th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat.com, AtriCure currently has a consensus rating of "Moderate Buy" and an average target price of $52.00.

AtriCure Stock Performance

Shares of ATRC opened at $54.54 on Monday. The business's 50 day moving average is $42.41 and its two-hundred day moving average is $33.56. AtriCure, Inc. has a 52-week low of $25.36 and a 52-week high of $55.72. The firm has a market cap of $2.77 billion, a price-to-earnings ratio of 259.73 and a beta of 1.26. The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14.

AtriCure (NASDAQ:ATRC - Get Free Report) last released its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. The business had revenue of $153.60 million during the quarter, compared to the consensus estimate of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same quarter last year, the company earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Analysts forecast that AtriCure, Inc. will post 0.29 EPS for the current fiscal year.

AtriCure Profile

AtriCure, Inc NASDAQ: ATRC is a medical device company focused on the treatment of atrial fibrillation (AF) and related conditions. The company develops, manufactures and sells surgical and minimally invasive technologies designed to restore normal heart rhythm and reduce the risk of stroke associated with AF.

Its product portfolio includes the AtriClip system for excluding the left atrial appendage, the Isolator and Synergy systems for surgical ablation, and the cryoICE system, which uses cryothermal energy in cardiac procedures.

Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure, Inc. (NASDAQ:ATRC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.